8-K current report · filed Aug 26, 2026

Celcuity Inc. (CELC) 8-K Current Report: August 26, 2026

Item 8.01Item 7.01CELC overview

Short answer

Celcuity Inc. (CELC) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Celcuity submitted an FDA supplemental NDA for REVTORPYK (gedatolisib).

Celcuity Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Celcuity submitted an FDA supplemental NDA for REVTORPYK (gedatolisib)
  • Target indication: HR-positive, HER2-negative locally advanced or metastatic breast cancer
  • Eligibility limited to patients with PIK3CA mutations after at least one endocrine-therapy line
  • FDA review creates a potential regulatory catalyst and expands gedatolisib’s commercial opportunity

Item 8.01 · Other Events

  • sNDA submitted to FDA for REVTORPYK in HR+/HER2- advanced breast cancer with PIK3CA mutations
  • Target population includes patients progressing after at least one endocrine-therapy line
  • FDA submission advances potential label expansion and creates a regulatory catalyst for Celcuity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Celcuity Inc. 8-K filings

Get the next CELC 8-K as it lands

Follow CELC for push alerts, or ask the research agent what this filing means.